The Modern Approaches and Future Perspectives on Breast and Ovarian Cancer Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers: A Literature Overview
DOI:
https://doi.org/10.12775/JEHS.2024.69.49454Keywords
BRCA mutation, breast cancer, ovarian cancer, cancer prevention, surveillance, screeningAbstract
Individuals with BRCA1 and BRCA2 mutations face significantly heightened likelihood of developing breast and ovarian cancers. Besides some lifestyle recommendations, like maintaining physical activity, healthy BMI, possibly early parenthood and breastfeeding, the management of BRCA1/2 mutation carriers includes gene mutation early-detection, screening, risk-reducing surgeries, and chemoprevention. Various prevention strategies exist, all aimed at monitoring patients and mitigating the cancer risks. However, even with the existence of national and international guidelines to direct prevention efforts, there is no ideal protocol that would be universally applicable for all individuals with mutated BRCA gene. This article aims to delve into the currently available surveillance and preventive strategies and explore the potential future avenues for early detection and risk reduction in BRCA mutation carriers.
References
Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866-871. doi:10.1111/j.1349-7006.2004.tb02195.x
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112
Litton JK, Ready K, Chen H, et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations [published correction appears in Cancer. 2012 Jun 1;118(11):2997]. Cancer. 2012;118(2):321-325. doi:10.1002/cncr.26284
Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009;46(9):593-597. doi:10.1136/jmg.2008.058248
Lee MV, Katabathina VS, Bowerson ML, et al. BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics. 2017;37(4):1005-1023. doi:10.1148/rg.2017160144
Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD, Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol. 2014;32(22):2304-2310. doi:10.1200/JCO.2013.52.5386
Naranjo ID, Sogani J, Saccarelli C, et al. MRI Screening of BRCA Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols With and Without T2-Weighted Images. AJR Am J Roentgenol. 2022;218(5):810-820. doi:10.2214/AJR.21.27022
Kemp Jacobsen K, O'Meara ES, Key D, et al. Comparing sensitivity and specificity of screening mammography in the United States and Denmark. Int J Cancer. 2015;137(9):2198-2207. doi:10.1002/ijc.29593
Lee MV, Katabathina VS, Bowerson ML, et al. BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics. 2017;37(4):1005-1023. doi:10.1148/rg.2017160144
Vreemann, S., van Zelst, J.C.M., Schlooz-Vries, M. et al. The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI. Breast Cancer Res 20, 84 (2018). https://doi.org/10.1186/s13058-018-1019-6
Koutras A, Perros P, Prokopakis I, Ntounis T, Fasoulakis Z, Pittokopitou S, Samara AA, Valsamaki A, Douligeris A, Mortaki A, et al. Advantages and Limitations of Ultrasound as a Screening Test for Ovarian Cancer. Diagnostics. 2023; 13(12):2078. https://doi.org/10.3390/diagnostics13122078
Funston G., Mounce L.TA., Price S., Rous B., Crosbie EJ., Hamilton W., Walter FM.,British Journal of General Practice 2021; 71 (707): e465-e472. DOI: 10.3399/BJGP.2020.0859
Nebgen DR, Lu KH, Bast RC Jr. Novel Approaches to Ovarian Cancer Screening. Curr Oncol Rep. 2019;21(8):75. Published 2019 Jul 26. doi:10.1007/s11912-019-0816-0
Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926-930. doi:10.1126/science.aar3247
Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748. Published 2018 Apr 5. doi:10.1002/14651858.CD002748.pub4
Bertozzi S, Londero AP, Xholli A, et al. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review. J Clin Med. 2023;12(4):1422. Published 2023 Feb 10. doi:10.3390/jcm12041422
Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature [published correction appears in Ann Surg Oncol. 2014 Dec;21 Suppl 4:S788. Weissman, Scott [added]]. Ann Surg Oncol. 2015;22(2):370-376. doi:10.1245/s10434-014-3883-3
Wei CH, Scott AM, Price AN, et al. Psychosocial and Sexual Well-Being Following Nipple-Sparing Mastectomy and Reconstruction. Breast J. 2016;22(1):10-17. doi:10.1111/tbj.12542
Cammarata E, Toia F, Rossi M, et al. Implant-Based Breast Reconstruction after Risk-Reducing Mastectomy in BRCA Mutation Carriers: A Single-Center Retrospective Study. Healthcare (Basel). 2023;11(12):1741. Published 2023 Jun 13. doi:10.3390/healthcare11121741
Riis ML. Management of patients with BRCA mutation from the point of view of a breast surgeon. Ann Med Surg (Lond). 2021;65:102311. Published 2021 Apr 16. doi:10.1016/j.amsu.2021.102311
Toyserkani NM, Jørgensen MG, Tabatabaeifar S, Damsgaard T, Sørensen JA. Autologous versus implant-based breast reconstruction: A systematic review and meta-analysis of Breast-Q patient-reported outcomes. J Plast Reconstr Aesthet Surg. 2020;73(2):278-285. doi:10.1016/j.bjps.2019.09.040
Tasoulis MK, Teoh V, Khan A, Montgomery C, Mohammed K, Gui G. Acellular dermal matrices as an adjunct to implant breast reconstruction: Analysis of outcomes and complications. Eur J Surg Oncol. 2020;46(4 Pt A):511-515. doi:10.1016/j.ejso.2019.10.042
Kotsopoulos J, Gronwald J, Karlan B, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2018;150(1):85-91. doi:10.1016/j.ygyno.2018.05.011
Daly MB, Pal T, Berry MP, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(1):77-102. Published 2021 Jan 6. doi:10.6004/jnccn.2021.0001
Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014;133(2):283-286. doi:10.1016/j.ygyno.2014.02.030
Marchetti C, De Felice F, Palaia I, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150. Published 2014 Dec 12. doi:10.1186/s12905-014-0150-5
Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(5):djv033. Published 2015 Mar 18. doi:10.1093/jnci/djv033
Saccardi C, Spagnol G, Saibene T, et al. Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1-2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients' Satisfaction of Multiple Surgeries. J Clin Med. 2022;11(24):7502. Published 2022 Dec 18. doi:10.3390/jcm11247502
Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L. No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer. J Obstet Gynaecol Can. 2018;40(11):1497-1510. doi:10.1016/j.jogc.2018.05.046
Trabert B, Tworoger SS, O'Brien KM, et al. The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). Cancer Res. 2020;80(5):1210-1218. doi:10.1158/0008-5472.CAN-19-2850
Park B, Hopper JL, Win AK, et al. Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers. Oncotarget. 2017;8(60):102110-102118. Published 2017 Oct 31. doi:10.18632/oncotarget.22193
Park J, Huang D, Chang YJ, Lim MC, Myung SK. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies. Carcinogenesis. 2022;43(3):231-242. doi:10.1093/carcin/bgab107
Patricia G. Moorman et al., Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. JCO 31, 4188-4198(2013). DOI:10.1200/JCO.2013.48.9021
Kathawala, R.J., Kudelka, A. & Rigas, B. The Chemoprevention of Ovarian Cancer: the Need and the Options. Curr Pharmacol Rep 4, 250–260 (2018). https://doi.org/10.1007/s40495-018-0133-6
Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med. 2019;23(4):2303-2313. doi:10.1111/jcmm.14133
Xu L, Zhao Y, Chen Z, Wang Y, Chen L, Wang S. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer. 2015;22(4):327-334. doi:10.1007/s12282-015-0619-6
Manna EDF, Serrano D, Aurilio G, Bonanni B, Lazzeroni M. Chemoprevention and Lifestyle Modifications for Risk Reduction in Sporadic and Hereditary Breast Cancer. Healthcare. 2023; 11(16):2360. https://doi.org/10.3390/healthcare11162360
Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21(1):134-147. doi:10.1158/1055-9965.EPI-11-0775
Singer CF. Nonsurgical Prevention Strategies in BRCA1 and BRCA2 Mutation Carriers. Breast Care (Basel). 2021;16(2):144-148. doi:10.1159/000507503
Kotsopoulos J, Singer C, Narod SA. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. Breast Cancer Res Treat. 2017;161(1):11-16. doi:10.1007/s10549-016-4029-z
Zaluzec EK, Sempere LF. Systemic and Local Strategies for Primary Prevention of Breast Cancer. Cancers (Basel). 2024;16(2):248. Published 2024 Jan 5. doi:10.3390/cancers16020248
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sandra Sarnacka, Jakub Kordialik, Julia Koćwin, Paula Bieganek, Bartosz Sadłowski, Stanisław Łukaszewicz, Piotr Pawłowski, Julia Rybak, Michał Tokarski, Angelika Banasiak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 122
Number of citations: 0